Compare CFG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFG | RPRX |
|---|---|---|
| Founded | 1828 | 1996 |
| Country | United States | United States |
| Employees | 17398 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4B | 22.0B |
| IPO Year | N/A | 2020 |
| Metric | CFG | RPRX |
|---|---|---|
| Price | $63.67 | $50.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $70.17 | $51.40 |
| AVG Volume (30 Days) | ★ 4.2M | 2.5M |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.86% | 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $20.17 | $38.63 |
| Revenue Next Year | $8.30 | $4.73 |
| P/E Ratio | ★ $16.85 | $27.84 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $37.93 | $31.97 |
| 52 Week High | $68.79 | $50.47 |
| Indicator | CFG | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 63.94 |
| Support Level | $58.09 | $35.35 |
| Resistance Level | $66.37 | N/A |
| Average True Range (ATR) | 1.46 | 0.91 |
| MACD | -0.24 | -0.03 |
| Stochastic Oscillator | 7.12 | 92.69 |
Citizens Financial Group Inc is a bank holding company headquartered in Providence, Rhode Island. Through its subsidiaries, it offers various retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations, and institutions. The group's reportable business segments are: Consumer Banking and Commercial Banking. The majority of its revenue is generated from the Consumer Banking segment, which serves consumer customers and small businesses, offering traditional banking products and services, including deposits, mortgage and home equity lending, credit cards, small business loans, education loans, point-of-sale finance loans, and wealth management solutions, among others, through a network of branches and ATMs.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.